Companies › TIXiMED
1 active drug program in 2 registered trials: 2 Phase 1; Metabolic and endocrine, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TIX100 thioredoxin-interacting protein (TXNIP) inhibitor | TXNIP | Phase 1 | Healthy; Health Adult Subjects | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06800729 | TIX100 | Phase 1 | Healthy | Other | May 2025 |
| NCT07675590 | TIX100 | Phase 1 | Health Adult Subjects | Metabolic and endocrine | Dec 2026 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.